{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:25Z","timestamp":1791252805461,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical trials evaluating chimeric antigen receptor (CAR) T\u2010cell therapy in relapsed\/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy of CAR T\u2010cell therapy in this patient population. We retrospectively reviewed eight consecutive patients with RRMM and AL amyloidosis who were treated with standard of care CAR T\u2010cell therapy. Cytokine release syndrome was seen in 75% of patients (grade\u2009\u22653: 0%) and immune effector cell\u2010associated neurotoxicity syndrome (grade 1) in only one patient. Low\u2010grade cytopenias were common (any grade\/grade \u22653: neutropenia 62.5%\/37.5%, anemia 37.5%\/0%, thrombocytopenia 25%\/0%). CAR T\u2010cell therapy led to rapid and deep responses with a median time to best response of 43\u2009days and a hematologic very good partial response or better rate of 62.5%. Overall, we found that commercial CAR T\u2010cell therapy was feasible, and effective in patients with RRMM and concurrent AL amyloidosis.<\/jats:p>","DOI":"10.1111\/ejh.14293","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T13:48:42Z","timestamp":1724766522000},"page":"817-823","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety and efficacy of <scp>B cell maturation antigen<\/scp>\u2010directed <scp>CAR T<\/scp>\u2010cell therapy in patients with relapsed\/refractory multiple myeloma and concurrent light chain amyloidosis"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-0325","authenticated-orcid":false,"given":"Utkarsh","family":"Goel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Center Cleveland Clinic  Cleveland Ohio USA"},{"name":"United States Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davis","sequence":"additional","affiliation":[{"name":"United States Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Department of Hematology\/Medical Oncology The Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"United States Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Shaikh","sequence":"additional","affiliation":[{"name":"United States Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"University of Iowa Holden Comprehensive Cancer Center  Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lochner","sequence":"additional","affiliation":[{"name":"University of Iowa Holden Comprehensive Cancer Center  Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u2010Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"United States Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Center Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"United States Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Myeloma &amp; Cell Therapy Service, Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Center Cleveland Clinic  Cleveland Ohio USA"},{"name":"United States Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006913"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00396"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02243-5"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30110697"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0637"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003783"},{"key":"e_1_2_9_12_1","volume-title":"Version 5.0","author":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1868810"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.100"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-767475"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570010"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081605"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.05.012"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14141"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186450"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00950-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022937"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T02:31:42Z","timestamp":1730860302000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/ejh.14293"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14293","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"2024-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}